Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma-Reference-Cited by-同舟云学术

Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma

Published:2013-07-23 Issue:3 Volume:98 Page:337-345
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Miyamoto Toshihiro,Yoshimoto Goichi,Kamimura Tomohiko,Muta Tsuyoshi,Takashima Shuichiro,Ito Yoshikiyo,Shiratsuchi Motoaki,Choi Ilseung,Kato Koji,Takenaka Katsuto,Iwasaki Hiromi,Takamatsu Yasushi,Teshima Takanori,Akashi Koichi

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-013-1402-0.pdf

Reference32 articles.

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.

2. Watanabe R, Tokuhira M, Kizaki M. Current approaches for the treatment of multiple myeloma. Int J Hematol. 2013;97:333–44.

3. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946–55.

4. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376:2075–85.

5. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–81.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT;Bone Marrow Transplantation;2024-01-31

2. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT;2023-09-22

3. High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma;Transplantation and Cellular Therapy;2022-09

4. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma;Leukemia;2020-04-23

5. Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation;International Journal of Hematology;2018-09-24